GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Northwest Biotherapeutics Inc (OTCPK:NWBO) » Definitions » PB Ratio

NWBO (Northwest Biotherapeutics) PB Ratio : (As of Apr. 04, 2025)


View and export this data going back to 2001. Start your Free Trial

What is Northwest Biotherapeutics PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2025-04-04), Northwest Biotherapeutics's share price is $0.2074. Northwest Biotherapeutics's Book Value per Share for the quarter that ended in Dec. 2024 was $-0.07. Hence, Northwest Biotherapeutics's PB Ratio of today is .

The historical rank and industry rank for Northwest Biotherapeutics's PB Ratio or its related term are showing as below:

NWBO's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.22
* Ranked among companies with meaningful PB Ratio only.

During the past 3 years, the average Book Value Per Share Growth Rate was 18.10% per year. During the past 5 years, the average Book Value Per Share Growth Rate was 16.50% per year. During the past 10 years, the average Book Value Per Share Growth Rate was 8.30% per year.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Northwest Biotherapeutics was 68.30% per year. The lowest was -28.70% per year. And the median was 25.25% per year.

Back to Basics: PB Ratio


Northwest Biotherapeutics PB Ratio Historical Data

The historical data trend for Northwest Biotherapeutics's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Northwest Biotherapeutics PB Ratio Chart

Northwest Biotherapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Northwest Biotherapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Northwest Biotherapeutics's PB Ratio

For the Biotechnology subindustry, Northwest Biotherapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Northwest Biotherapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Northwest Biotherapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Northwest Biotherapeutics's PB Ratio falls into.


;
;

Northwest Biotherapeutics PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Northwest Biotherapeutics's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2024)
=0.2074/-0.072
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Northwest Biotherapeutics  (OTCPK:NWBO) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Northwest Biotherapeutics PB Ratio Related Terms

Thank you for viewing the detailed overview of Northwest Biotherapeutics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Northwest Biotherapeutics Business Description

Traded in Other Exchanges
Address
4800 Montgomery Lane, Suite 800, Bethesda, MD, USA, 20814
Northwest Biotherapeutics Inc is a biotechnology company involved in the development of cancer vaccines. The target is a broad range of solid-tumor cancers. The company has a proprietary manufacturing technology, which it uses to produce a personalized vaccine. The product portfolio includes product candidates such as DCVax-L, for patients with brain cancer; DCVax-Direct, direct injection into all types of inoperable solid tumor cancers, and DCVax for late-stage ovarian cancer. DCVax-Prostate, for late-stage prostate cancer, has received clearance from the U.S. Food and Drug Administration.
Executives
Navid Malik director 1 CHOLMELEY PARK, HIGHGATE, LONDON X0 N6 5ET
Marnix L Bosch officer: Chief Technical Officer 22322 20TH AVENUE SE, STE 250, BOTHELL WA 98021
Alton L Boynton director, officer: Chief Scientific Officer 22322 20TH AVENUE SE, STE 150, BOTHELL WA 98021
Leslie J. Goldman officer: See Remarks C/O NORTHWEST BIOTHERAPEUTICS, INC., 4800 MONTGOMERY LANE, SUITE 800, NEW YORK NY 20814
Linda F Powers director, 10 percent owner, officer: President and CEO 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Jerry J Jasinowski director C/O HARSCO CORP, P O BOX 8888, CAMP HILL PA 17001-8888
Jean M. Davis officer: See Remarks 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Susan B Bayh director WELLPOINT, INC., 120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Black Cofer director 4800 MONTGOMERY LANE, SUITE 800, BETHESDA MD 20814
Woodford Investment Management Llp 10 percent owner 27 OLD GLOUCESTER STREET, LONDON X0 WC1N 3AX
Cf Woodford Equity Income Fund 10 percent owner C/O WOODFORD INVESTMENT MANAGEMENT LTD, 9400 GARSINGTON ROAD, OXFORD X0 OX4 2HN
Cognate Bioservices, Inc. 10 percent owner 7513 CONNELLEY DRIVE, HANOVER MD 21076
Robert A Farmer director 10205 COLLINS AVE PENTHOUSE 6, MIAMI BEACH FL 33154
Toucan General Ii, Llc 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814
Hemphill Robert F Jr. 10 percent owner 7600 WISCONSIN AVENUE, SUITE 700, BETHESDA MD 20814

Northwest Biotherapeutics Headlines

From GuruFocus

Northwest Biotherapeutics Announces $15 Million Financing

By PRNewswire PRNewswire 11-29-2021